Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,042,152,720.94, representing a year-on-year increase of 12.53%[4] - The net profit attributable to shareholders was CNY 153,203,982.25, showing a slight decrease of 1.93% compared to the same period last year[4] - The company reported a net profit margin improvement, with net profit for Q1 2022 expected to be higher than the previous year, although specific figures were not disclosed[18] - The company's net profit for Q1 2022 was ¥153,203,982.25, a decrease of 1.3% compared to ¥156,226,670.04 in Q1 2021[20] - Operating profit for Q1 2022 was ¥187,394,576.30, slightly up from ¥186,068,031.49 in the same period last year[20] - The company reported a total profit of ¥183,751,708.39, down from ¥185,897,554.63 in Q1 2021[20] - Total revenue from sales and services received cash of ¥799,487,536.33, an increase of 6.2% from ¥752,816,754.48 in Q1 2021[22] - The basic and diluted earnings per share remained stable at ¥0.26 for both Q1 2022 and Q1 2021[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -38,813,883.36[4] - Cash flow from operating activities was negative at -¥38,813,883.36, an improvement from -¥61,359,543.88 in Q1 2021[23] - Cash flow from investment activities was negative at -¥98,152,854.78, compared to -¥552,144,694.65 in the same quarter last year[23] - The company’s cash and cash equivalents at the end of Q1 2022 were ¥569,953,519.22, a decrease from ¥707,994,577.34 at the beginning of the quarter[23] - Cash and cash equivalents decreased to RMB 755,303,339.19 as of March 31, 2022, down from RMB 885,044,113.42 at the end of 2021, a decline of 14.7%[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,465,433,169.32, an increase of 0.87% from the end of the previous year[5] - Total assets amounted to RMB 6,465,433,169.32 as of March 31, 2022, compared to RMB 6,409,715,397.53 at the end of 2021, a slight increase of 0.9%[16] - Total liabilities decreased to RMB 1,639,399,167.99 from RMB 1,739,411,613.91 at the end of 2021, a reduction of 5.7%[17] - The equity attributable to shareholders increased by 3.33% to CNY 4,826,034,001.33 compared to the end of the previous year[5] - Shareholders' equity increased to RMB 4,826,034,001.33 as of March 31, 2022, compared to RMB 4,670,303,783.62 at the end of 2021, reflecting a growth of 3.3%[17] Expenses - The company's sales expenses increased significantly by 144.62% compared to the same period last year, primarily due to increased freight and travel expenses[9] - The company's financial expenses rose by 72.62% year-on-year, mainly due to a decrease in interest income[9] - Total operating costs for Q1 2022 were RMB 843,741,637.41, up from RMB 754,319,685.85 in Q1 2021, reflecting a year-over-year increase of 11.8%[18] - Research and development expenses were ¥33,596,760.33, down from ¥36,357,460.15 in the previous year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 77,442[10] - The largest shareholder, Shandong Luzhong Investment Co., Ltd., held 21.75% of the shares, amounting to 129,380,980 shares[11] Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[18]
山东药玻(600529) - 2022 Q1 - 季度财报